« previous next »
Pages: [1] 2

Author Topic: Aspen Pharmacare  (Read 39807 times)

jaDEB

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 4551
  • Karma: +31/-3
    • View Profile
Aspen Pharmacare
« on: June 28, 2013, 10:38:14 am »
Why did we miss this one?

 ???  ???
Logged
jaDEB

If it scares you, it's a sign you need to do it

Patrick

  • Administrator
  • Hero Member
  • *****
  • Posts: 2551
  • Karma: +47/-2
    • View Profile
Re: Aspen Pharmacare
« Reply #1 on: June 28, 2013, 10:43:49 am »
Quote from: jaDEB on June 28, 2013, 10:38:14 am
Why did we miss this one?

 ???  ???

Haha funny enough we didn't. I just posted in the long term thread reminding about my choice  :D

Orca I'm breathing down your neck in the contest!
Logged

Patrick

  • Administrator
  • Hero Member
  • *****
  • Posts: 2551
  • Karma: +47/-2
    • View Profile
Re: Aspen Pharmacare
« Reply #2 on: June 28, 2013, 10:46:23 am »
Quote
(Reuters) - Aspen Pharmacare said on Thursday that it would acquire drugs and a plant from U.S. firm Merck in a $1 billion deal that bolsters its presence in Europe, Latin America and Asia.

Africa's biggest maker of generic drugs said it would buy an active pharmaceutical ingredient (API) business located in the Netherlands and a portfolio of 11 drug brands from Merck.

Aspen said the deal was subject to the approval of various competition authorities and the South African Reserve Bank.

Last week, Aspen said it would acquire the Arixtra and Fraxiparine/Fraxodi brands of thrombosis drugs from GlaxoSMithKline, except in China, Pakistan and India, a deal that could also be worth $1 billion.

Shares in Aspen, rose more than 1 percent on the news, outperforming a 0.7 percent decline in Johannesburg's benchmark Top-40 index.

http://www.reuters.com/article/2013/06/27/us-aspen-merck-idUSBRE95Q0H520130627
Logged

Orca

  • Hero Member
  • *****
  • Posts: 2280
  • Karma: +54/-3
    • View Profile
Re: Aspen Pharmacare
« Reply #3 on: June 28, 2013, 12:24:28 pm »
Quote from: Patrick on June 28, 2013, 10:43:49 am
Quote from: jaDEB on June 28, 2013, 10:38:14 am
Why did we miss this one?

 ???  ???

Haha funny enough we didn't. I just posted in the long term thread reminding about my choice  :D

Orca I'm breathing down your neck in the contest!

Yea. But I'll be eating your dust soon. CML just cannot go any higher at this stage.
Logged
I started here with nothing and still have most of it left.

Moonraker

  • Hero Member
  • *****
  • Posts: 1095
  • Karma: +31/-0
    • View Profile
Re: Aspen Pharmacare
« Reply #4 on: November 20, 2013, 07:11:17 pm »
Hoping for a bounce back soon, now that Glaxo has completed their partial sale of APN stock.

GSK completes sale of Aspen shares

But what about that LT trade of 9,940,000 @250  ??

In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008 (“the Act”), and section
3.83(b) of the JSE Listings Requirements, holders of ordinary shares in the Company are advised
that:

Glaxo Group Limited (“GSK”), has disposed of Aspen Holdings ordinary shares, such that its
beneficial interests in Aspen Holdings now amounts to 12.4% of the total number of shares in
issue.



Last 10 Trades of the day

Date                PDT     Price     Volume

20/11 17:50   LT   25000   9,940,000

20/11 17:48   OP   25743   308

20/11 17:45   OP   25716   79,122

20/11 17:44   OP   25692   1,000,000

20/11 17:37   OP   25652   350,000

20/11 17:00   OCP   25700   0

20/11 17:00   AT   25700   138,022

20/11 16:49   AT   25699   100

20/11 16:49   AT   25699   466

20/11 16:49   AT   25699   89
Logged

Moonraker

  • Hero Member
  • *****
  • Posts: 1095
  • Karma: +31/-0
    • View Profile
Re: Aspen Pharmacare
« Reply #5 on: November 21, 2013, 09:24:54 am »
Quote
GSK said the sale of the shares would not affect its relationship with Aspen. "GSK has a long and successful partnership with Aspen — and our investment in the company has grown in value significantly over time. Having assessed this investment we have now decided to realise some of this value without altering the basis of the partnership," GSK chief strategy officer David Redfern said.

"We remain committed to working closely with Aspen as shown by our remaining stake in the company and our board seat," he said in a statement.

GSK acquired a stake in Aspen in 2009 when the two drug makers entered into two collaborations in sub-Saharan Africa. Aspen has since acquired a number of over-the-counter and prescription brands from GSK which the UK company considered to be noncore. Aspen recently bought GSK’s thrombosis products Arixtra and Fraxiparine and their associated manufacturing site for £800m. The transaction was approved by Aspen shareholders on November 8 and is expected to close at the end of the year, according to GSK.

Aspen deputy group CE Gus Attridge said: "Aspen’s relationship with GSK remains strong. They continue to serve on our board and both Aspen and GSK believe our relationship will continue to be mutually beneficial."

Africfocus analyst Alec Abraham said that he believed the market’s response to GSK’s sale of part of its stake in Aspen was overblown as Aspen’s business remained unchanged.

GSK said the R7.059bn raised by the share sale would be used for "general corporate purposes".

Source
Logged

jaDEB

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 4551
  • Karma: +31/-3
    • View Profile
Re: Aspen Pharmacare
« Reply #6 on: April 30, 2014, 03:25:44 pm »
BUMP...

 8)
Logged
jaDEB

If it scares you, it's a sign you need to do it

jaDEB

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 4551
  • Karma: +31/-3
    • View Profile
Re: Aspen Pharmacare
« Reply #7 on: October 09, 2014, 03:31:11 pm »
JOHANNESBURG (Reuters) - South Africa generic drugmaker Aspen Pharmacare has teamed up with shareholder GlaxoSmithKline PLC to extend its foothold in Japan, a lucrative market for low-cost medicines, it said on Thursday.
Aspen, Africa's biggest generic drugmaker, would sell a 25 percent stake in a newly established Japanese business to GlaxoSmithKline, which already owns about 12 percent of Aspen.
Under the deal, GlaxoSmithKline would transfer distribution rights of certain products to the new entity, Aspen Japan. GSK would also provide Aspen Japan with a pipeline for a number generic medicines.
Politicians in the world's second-biggest pharmaceutical market are lobbying for more generic drugs to go on sale to bring down the cost of healthcare for a rapidly ageing population.
Shares in Aspen climbed 4.3 percent to 354.51 rand by 1050 GMT, outpacing 1.5 percent gain in the JSE Top-40 index.
Logged
jaDEB

If it scares you, it's a sign you need to do it

jaDEB

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 4551
  • Karma: +31/-3
    • View Profile
Re: Aspen Pharmacare
« Reply #8 on: March 13, 2015, 09:21:51 am »
 :frustrated:

GSK ANNOUNCES COMPLETION OF THE SALE OF HALF ITS STAKE IN ASPEN

GlaxoSmithKline (“GSK”) has announced the completion of the disposal of half of its 12.4% shareholding in
Aspen (equivalent to 28.2 million ordinary shares). These shares were sold by means of an accelerated book
build offering process which resulted in the shares being sold at ZAR 372 per share, raising gross proceeds
of approximately ZAR 10.5 billion.

Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing
approximately 6.2% of the issued share capital.

Simon Dingemans, GSK’s Chief Financial Officer, said: “GSK has a long and successful commercial
partnership with Aspen and our investment in the company has grown in value significantly over time. As
we continue to reshape the Group around our core franchises and drive the benefits from the Novartis
transaction, optimizing our financial flexibility to invest behind these priorities is key. As a result we have
decided now is the right time to realise further value from this successful relationship. We continue to
believe in the strategy of Aspen and we remain committed to working together in the future.”

The Board of Aspen has agreed that Mr David Redfern, recently appointed as GSK’s nominee director to
replace Mr Abbas Hussain on the Board, will remain a director of Aspen.


Durban
13 March 2015
Logged
jaDEB

If it scares you, it's a sign you need to do it

Hamster

  • Hero Member
  • *****
  • Posts: 535
  • Karma: +13/-0
    • View Profile
    • Off Topic
Re: Aspen Pharmacare
« Reply #9 on: April 29, 2015, 10:57:36 am »
Down down down down.... :'(
Logged

jaDEB

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 4551
  • Karma: +31/-3
    • View Profile
Re: Aspen Pharmacare
« Reply #10 on: April 29, 2015, 11:20:52 am »
Ditto ..   :wall:  :wall:

And I do not know why ...

Logged
jaDEB

If it scares you, it's a sign you need to do it

Hamster

  • Hero Member
  • *****
  • Posts: 535
  • Karma: +13/-0
    • View Profile
    • Off Topic
Re: Aspen Pharmacare
« Reply #11 on: April 29, 2015, 11:33:02 am »
So the question is - sell or hold, sell or hold?

My head is telling me to hold since I do not have that much in it and that it might bounce back, but that might be naive. Maybe its run is over (we're already back to OCt 14 levels).
Logged

jaDEB

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 4551
  • Karma: +31/-3
    • View Profile
Re: Aspen Pharmacare
« Reply #12 on: April 29, 2015, 05:14:58 pm »
i WILL Be KEePiNG minE .....
Logged
jaDEB

If it scares you, it's a sign you need to do it

JDP

  • Jr. Member
  • **
  • Posts: 88
  • Karma: +3/-0
    • View Profile
Re: Aspen Pharmacare
« Reply #13 on: May 05, 2015, 08:23:16 pm »
FYI. Trading Central.

Our pivot point stands at 37705.

Our preference: the downside prevails as long as 37705 is resistance.

Alternative scenario: above 37705, look for 39238 and 40187.

Comment: the RSI is below 30. It could either mean that the stock is in a lasting downtrend or just oversold
and therefore bound to retrace (look for bullish divergence in this case). The MACD is below its signal line
and negative. The configuration is negative. Moreover, the share stands below its 20 and 50 day MA
(respectively at 38599.65 and 39682.58).

Logged

jaDEB

  • Global Moderator
  • Hero Member
  • *****
  • Posts: 4551
  • Karma: +31/-3
    • View Profile
Re: Aspen Pharmacare
« Reply #14 on: May 11, 2015, 02:05:45 pm »
elease Date: 11/05/2015 13:30:00      Code(s): APN     [Email this JSE Sens Item to a Friend]   [Printer Friendly Version]

Divestment of South African Business Unit to Litha

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)

DIVESTMENT OF SOUTH AFRICAN BUSINESS UNIT TO LITHA

Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of
Aspen Holdings and the Group’s primary South African trading company, has concluded a set of
agreements with Litha Pharma (Pty) Ltd ("Litha") (a wholly owned South African subsidiary of Endo
International Plc) in terms which Pharmacare will divest a business unit which forms part of its
pharmaceutical division to Litha for a consideration of approximately R1.6 billion (“the Transaction”).

The business unit concerned has a product portfolio comprising injectables and established brands. This
portfolio recorded revenue of R362 million and a direct contribution to profit before tax of R136 million for
the year ended 30 June 2014.

The Transaction forms part of Aspen’s communicated strategic intent to focus attention in areas where
most value can be added and to lessen complexity.

The Transaction is conditional upon, inter alia, the approval of the South African Competition Authorities.


Durban

11 May 2015
Logged
jaDEB

If it scares you, it's a sign you need to do it
Pages: [1] 2
« previous next »